Table: Eisai 6-MTH group results (IFRS)
Nov 5 (Reuters)-
Eisai Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months ended 6 months ended Year to
Sep 30, 2025 Sep 30, 2024 Mar 31, 2026
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 400.01 385.02 790.00
(+3.9 pct) (+3.1 pct) (+0.1 pct)
Operating 34.42 27.84 54.50
(+23.6 pct) (-11.4 pct) (+0.2 pct)
Pretax 36.94 31.54 59.00
(+17.1 pct) (-11.6 pct) (-3.4 pct)
Net 24.63 21.69 41.50
(+13.5 pct) (-6.2 pct) (-10.6 pct)
EPS Basic 87.37 yen 76.13 yen 147.20 yen
Ann Div 160.00 yen 160.00 yen
-Q2 Div 80.00 yen 80.00 yen
-Q4 Div 80.00 yen 80.00 yen
NOTE - Eisai Co Ltd.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4523.T
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China